Influential Factors and Efficacy Analysis of Tacrolimus Concentration After Allogeneic Hematopoietic Stem Cell Transplantation in Children with β-Thalassemia Major

References

• Taher AT, Musallam KM, Cappellini MD. Β-thalassemias. N Engl J Med. 2021;384(8):727–743. doi:10.1056/NEJMra2021838
   PubMed Web of Science ®Google Scholar
• Huang B, Lin X, Zhang Z, et al. Comparison of tacrolimus and cyclosporine combined with methotrexate for graft versus host disease prophylaxis after allogeneic hematopoietic cell transplantation. Transplantation. 2020;104(2):428–436. doi:10.1097/TP.0000000000002836
   PubMed Web of Science ®Google Scholar
• El-Hamamsy M, Montasser IF, Mansy AE, et al. Effect of cyclosporine a versus tacrolimus on the response to antiviral therapy after hepatitis c genotype-4 recurrence post-liver transplantation: a prospective cohort trial. J Clin Pharm Ther. 2019;44(3):447–453. doi:10.1111/jcpt.12807
   Web of Science ®Google Scholar
• Miano TA, Flesch JD, Feng R, et al. Early tacrolimus concentrations after lung transplant are predicted by combined clinical and genetic factors and associated with acute kidney injury. Clin Pharmacol Ther. 2020;107(2):462–470. doi:10.1002/cpt.1629
   PubMed Web of Science ®Google Scholar
• Hart A, Smith JM, Skeans MA, et al. Optn/srtr 2017 annual data report: kidney. Am J Transplant. 2019;19(Suppl 2):19–123. doi:10.1111/ajt.15274
   PubMedGoogle Scholar
• Yu M, Liu M, Zhang W, et al. Pharmacokinetics, pharmacodynamics and pharmacogenetics of tacrolimus in kidney transplantation. Curr Drug Metab. 2018;19(6):513–522. doi:10.2174/1389200219666180129151948
   PubMed Web of Science ®Google Scholar
• Ling Q, Huang H, Han Y, et al. The tacrolimus-induced glucose homeostasis imbalance in terms of the liver: from bench to bedside. Am J Transplant. 2020;20:701–713.
   Web of Science ®Google Scholar
• Lue A, Martinez E, Navarro M, et al. Donor age predicts calcineurin inhibitor induced neurotoxicity after liver transplantation. Transplantation. 2019;103(8):e211–e215. doi:10.1097/TP.0000000000002750
   Web of Science ®Google Scholar
• Tholking G, Schutte-Nutgen K, Schmitz J, et al. A low tacrolimus concentration/dose ratio increases the risk for the development of acute calcineurin inhibitor-induced nephrotoxicity. J Clin Med. 2019;8(10):1586. doi:10.3390/jcm8101586
   Web of Science ®Google Scholar
• Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet. 1995;29(6):404–430. doi:10.2165/00003088-199529060-00003
   PubMed Web of Science ®Google Scholar
• Prasad N, Jaiswal A, Behera MR, et al. Melding pharmacogenomic effect of mdr1 and cyp3a5 gene polymorphism on tacrolimus dosing in renal transplant recipients in northern India. Kidney Int Rep. 2020;5(1):28–38. doi:10.1016/j.ekir.2019.09.013
   Web of Science ®Google Scholar
• Vanhove T, Annaert P, Kuypers DR. Clinical determinants of calcineurin inhibitor disposition: a mechanistic review. Drug Metab Rev. 2016;48(1):88–112. doi:10.3109/03602532.2016.1151037
   PubMed Web of Science ®Google Scholar
• Venkataramanan R, Zang S, Gayowski T, Singh N. Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antimicrob Agents Chemother. 2002;46(9):3091–3093. doi:10.1128/AAC.46.9.3091-3093.2002
   PubMed Web of Science ®Google Scholar
• Tron C, Woillard JB, Houssel-Debry P, et al. Pharmacogenetic-whole blood and intracellular pharmacokinetic-pharmacodynamic (pg-pk2-pd) relationship of tacrolimus in liver transplant recipients. PLoS One. 2020;15(3):e0230195. doi:10.1371/journal.pone.0230195
   PubMed Web of Science ®Google Scholar
• Lemaitre F, Antignac M, Fernandez C. Monitoring of tacrolimus concentrations in peripheral blood mononuclear cells: application to cardiac transplant recipients. Clin Biochem. 2013;46(15):1538–1541. doi:10.1016/j.clinbiochem.2013.02.011
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute gvhd grading. Bone Marrow Transplant. 1995;15(6):825–828.
   PubMed Web of Science ®Google Scholar
• Chalasani NP, Hayashi PH, Bonkovsky HL, et al. Acg clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109(7):950–966. doi:10.1038/ajg.2014.131
   PubMed Web of Science ®Google Scholar
• Hayashi PH, Fontana RJ. Clinical features, diagnosis, and natural history of drug-induced liver injury. Semin Liver Dis. 2014;34(2):134–144. doi:10.1055/s-0034-1375955
   PubMed Web of Science ®Google Scholar
• Möller A, Iwasaki K, Kawamura A, et al. The disposition of 14c-labeled tacrolimus after intravenous and oral administration in healthy human subjects. Drug Metab Dispos. 1999;27(6):633–636.
   PubMed Web of Science ®Google Scholar
• Hendijani F, Azarpira N, Kaviani M. Effect of cyp3a5*1 expression on tacrolimus required dose for transplant pediatrics: a systematic review and meta-analysis. Pediatr Transplant. 2018;22(6):e13248. doi:10.1111/petr.13248
   Web of Science ®Google Scholar
• Hamadeh IS, Zhang Q, Steuerwald N, et al. Effect of cyp3a4, cyp3a5, and abcb1 polymorphisms on intravenous tacrolimus exposure and adverse events in adult allogeneic stem cell transplant patients. Biol Blood Marrow Transplant. 2019;25(4):656–663. doi:10.1016/j.bbmt.2018.12.766
   PubMed Web of Science ®Google Scholar
• Peksa GD, Schultz K, Fung HC. Dosing algorithm for concomitant administration of sirolimus, tacrolimus, and an azole after allogeneic hematopoietic stem cell transplantation. J Oncol Pharm Pract. 2015;21(6):409–415. doi:10.1177/1078155214539825
   PubMed Web of Science ®Google Scholar
• Kanamitsu K, Yorifuji T, Ishida H, et al. Clinical factors affecting the dose conversion ratio from intravenous to oral tacrolimus formulation among pediatric hematopoietic stem cell transplantation recipients. Ther Drug Monit. 2020;42(6):803–810. doi:10.1097/FTD.0000000000000793
   Web of Science ®Google Scholar
• Suetsugu K, Ikesue H, Miyamoto T, et al. Analysis of the variable factors influencing tacrolimus blood concentration during the switch from continuous intravenous to oral administration after allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2017;105(3):361–368. doi:10.1007/s12185-016-2135-7
   Web of Science ®Google Scholar
• de Jonge H, Vanhove T, de Loor H, et al. Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing cyp3a4 activity and increasing haematocrit. Br J Clin Pharmacol. 2015;80(3):548–559. doi:10.1111/bcp.12703
   Web of Science ®Google Scholar
• Ji E, Kim MG, Oh JM. Cyp3a5 genotype-based model to predict tacrolimus dosage in the early postoperative period after living donor liver transplantation. Ther Clin Risk Manag. 2018;14:2119–2126. doi:10.2147/TCRM.S184376
   PubMed Web of Science ®Google Scholar
• Zhang HJ, Li DY, Zhu HJ, et al. Tacrolimus population pharmacokinetics according to cyp3a5 genotype and clinical factors in Chinese adult kidney transplant recipients. J Clin Pharm Ther. 2017;42(4):425–432. doi:10.1111/jcpt.12523
   PubMed Web of Science ®Google Scholar
• Chinnadurai R, Ibrahim ST, Tay T, et al. Body weight-based initial dosing of tacrolimus in renal transplantation: is this an ideal approach? J Ren Care. 2021;47(1):51–57. doi:10.1111/jorc.12339
   Web of Science ®Google Scholar
• Flabouris K, Chadban S, Ladhani M, et al. Body mass index, weight-adjusted immunosuppression and the risk of acute rejection and infection after kidney transplantation: a cohort study. Nephrol Dial Transplant. 2019;34(12):2132–2143. doi:10.1093/ndt/gfz095
   Web of Science ®Google Scholar
• Wallemacq P, Armstrong VW, Brunet M, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit. 2009;31(2):139–152. doi:10.1097/FTD.0b013e318198d092
   PubMed Web of Science ®Google Scholar
• Brunet M, van Gelder T, Asberg A, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. Ther Drug Monit. 2019;41(3):261–307.
   PubMed Web of Science ®Google Scholar
• Winkler M, Ringe B, Baumann J, et al. Plasma vs whole blood for therapeutic drug monitoring of patients receiving fk 506 for immunosuppression. Clin Chem. 1994;40(12):2247–2253. doi:10.1093/clinchem/40.12.2247
   Web of Science ®Google Scholar
• Kershner RP, Fitzsimmons WE. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation. 1996;62(7):920–926. doi:10.1097/00007890-199610150-00009
   PubMed Web of Science ®Google Scholar
• Erden E, Warty V, Magnone M, et al. Plasma FK506 levels in patients with histopathologically documented renal allograft rejection. Transplantation. 1994;58(3):397–398. doi:10.1097/00007890-199408000-00031
   Web of Science ®Google Scholar
• Japanese FK 506 Study Group. Morphological characteristics of renal allografts showing renal dysfunction under fk 506 therapy: is graft biopsy available to reveal the morphological findings corresponding with fk 506 nephropathy? Transplant Proc. 1993;25(1 Pt 1):624–627.
   Web of Science ®Google Scholar
• Bonong PR, Zahreddine M, Buteau C, et al. Factors associated with post-transplant active Epstein-Barr virus infection and lymphoproliferative disease in hematopoietic stem cell transplant recipients: a systematic review and meta-analysis. Vaccines. 2021;9(3):288.
   Web of Science ®Google Scholar
• Beswick J, Shin E, Michelis FV, et al. Incidence and risk factors for nontuberculous mycobacterial infection after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2018;24(2):366–372. doi:10.1016/j.bbmt.2017.09.015
   Web of Science ®Google Scholar
• Deng R, Liao Y, Li Y, et al. Association of cyp3a5, cyp2c8, and abcb1 polymorphisms with early renal injury in Chinese liver transplant recipients receiving tacrolimus. Transplant Proc. 2018;50(10):3258–3265. doi:10.1016/j.transproceed.2018.06.040
   Web of Science ®Google Scholar
• Taniai N, Akimaru K, Ishikawa Y, et al. Hepatotoxicity caused by both tacrolimus and cyclosporine after living donor liver transplantation. J Nippon Med Sch. 2008;75(3):187–191. doi:10.1272/jnms.75.187
   PubMedGoogle Scholar
• Marquet P, Destère A, Monchaud C, et al. Clinical pharmacokinetics and bayesian estimators for the individual dose adjustment of a generic formulation of tacrolimus in adult kidney transplant recipients. Clin Pharmacokinet. 2020;60(5):611–622. doi:10.1007/s40262-020-00959-y
   Web of Science ®Google Scholar